Transparency requirement (FSA/AKG)
According to the FSA e. V. (Voluntary Self-Regulation for the Pharmaceutical Industry), the conditions and scope of support from member companies must be presented transparently to participants, both when announcing and conducting the congress.
In accordance with the guidelines of the AKG e. V. (Arzneimittel und Kooperation im Gesundheitswesen e.V.), member companies must work towards ensuring that their support is disclosed by the organiser both when announcing the congress and during its implementation. The publication of the type and scope of the overall support does not represent an obligation for the AKG member companies and is voluntary here.
Industry partner | Amount | Purpose of the support | |
---|---|---|---|
B. Braun Avitum AG | 3.480,00 € | exhibition space | |
Daiichi Sankyo Deutschland GmbH | 15.000,00 € | Sponsoring Package Silver | |
DIAMED Medizintechnik GmbH | 3.375,60 € | exhibition space | |
Kaneka Pharma Europe N.V. | 4.176,00 € | exhibition space | |
Sanofi-Aventis Deutschland GmbH | 3.850,00 € | exhibition booth |
The industry partners confirm that the support service is not intended to influence sales transactions, in particular procurement transactions/pricing, or the prescribing behaviour of the medical facility, nor are there any expectations in this regard.
We are pleased to announce that Joint 14th ISFA World Congress and the 4th E-ISFA European Congress 2023 has been assessed as COMPLIANT by